New clinical data showed an experimental drug called pertuzumab prolonged the survival time for women with recurrent ovarian cancer, a University of Alabama at Birmingham doctor said recently.The data was presented during a scientific session of the 14th European Cancer Conference held in Barcelona, Spain. The session’s main speaker was Sharmila Makhija, M.D., an associate professor in UAB’s Division of Gynecologic Oncology. [click link for full article]